Moderna and Merck report 42% reduction in melanoma death and recurrence with mRNA vaccine
Moderna and Merck have released topline results from a melanoma trial of a personalized mRNA cancer vaccine, reporting a 42% reduction in death and recurrence.
The companies had previously announced that the trial succeeded. The new results provide a specific headline figure, but the supplied report does not include details about participant numbers, follow-up duration, statistical measures, or the vaccine’s safety profile.
The findings remain company-reported at this stage, with fuller trial information needed to assess the scale and limitations of the result.